Cost‐effectiveness of pancreas surveillance: The CDKN2A‐p16‐Leiden cohort
Sign Up to like & getrecommendations! Published in 2023 at "United European Gastroenterology Journal"
DOI: 10.1002/ueg2.12360
Abstract: Abstract Background CDKN2A‐p16‐Leiden mutation carriers have a high lifetime risk of developing pancreatic ductal adenocarcinoma (PDAC), with very poor survival. Surveillance may improve prognosis. Objective To assess the cost‐effectiveness of surveillance, as compared to no… read more here.
Keywords: cdkn2a p16; surveillance; cost; cost effectiveness ... See more keywords